Journal of Clinical Haematology

Research Article Open Access

Thrombotic Events and Risk Factors for Thrombosis in Polycythemia in Senegal, West Africa

Moussa Seck , Elimane Seydi Bousso , Sokhna Aissatou Touré , Abibatou Sall , Maryama Ndao , Sérigne Mourtalla Guèye , Blaise Félix Faye , Alioune Badara Diallo , Mohamed Keita , Awa Oumar Touré , Saliou Diop

Objectives: We aim to identify thrombotic events and risk factors for thrombosis (RFT) comparing polycythemia vera (PV) and secondary polycythemia (SP) patients. Methods: We carried out a retrospective study of a cohort of 59 patients with PV (n=34) and SP (n=25) followed for a period of 14 years. Variables studied were the frequency and type of thrombosis, sociodemographic, clinical, and biological RFT. Statistical analysis was performed using SPSS software version 18. Multivariate analysis was performed to identify RFT.

J Clin Haematol, 2023, Volume 4, Issue 1, p1-8 | DOI: 10.33696/haematology.4.052

Review Article Open Access

A Rare Blood Malignancy in a Genetic Hematological Disorder: Polycythemia Vera (PV) in Sickle Cell Disease (SCD)

Christopher L. Edwards , Sharena Scott , Michaela Boggan , Jordan Meek , W. Jeff Bryson , Alexandria McDougald , Milo Broadnax , Camela S. Barker , Jessica Miller , John J. Sollers , Tanisha Burford , Jonathan Livingston , Elaine Whitworth , Goldie S. Byrd , Kelvin L. Williams , Sherry Eaton , Malik Muhammad , George Cliette , Dana Jones , Brianna Downey , Hilary T. Dietahin , Merrell Turner , Roland Thorpe , Keith Whitfield , Debra O. Parker , Elwood Robinson , Mary Wood , Kenyon Railey , Shiv Sudhakar , Wandy Morel Cubilete , Nirmish Shah

To delineate the etiology, symptomatology, and treatment of Polycythemia Vera in adults with Sickle Cell Disease. The current review contains a review of the 4 case reports that we found on the topic. To our knowledge, no other case reports exist.

J Clin Haematol, 2023, Volume 4, Issue 1, p9-19 | DOI: 10.33696/haematology.4.053

Research Article Open Access

Molecular Features Associated with Response to Enasidenib Plus Azacitidine in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia

Alberto Risueño , Wendy L. See , Thomas Prebet , Courtney DiNardo , Hartmut Döhner , Eytan M. Stein , Amir T. Fathi , Paresh Vyas , Lynn Quek , Anita Gandhi , Maroof Hasan

IDH2 gene mutations, typically at residues R140 and R172, occur in 8–19% of patients with acute myeloid leukemia (AML). These mutations induce production of 2-hydroxyglutarate (2-HG), an oncometabolite that causes DNA and histone hypermethylation, and subsequent blockade of hematopoietic cell differentiation.

J Clin Haematol, 2023, Volume 4, Issue 1, p20-34 | DOI: 10.33696/haematology.4.054